What do you all think about this?

This forum made possible through the generous support of SDN members, donors, and sponsors. Thank you.

Stillinscrubs

Member
10+ Year Member
5+ Year Member
15+ Year Member
Joined
Dec 10, 2005
Messages
34
Reaction score
0
According to the Wall Street Journal they are not getting imformed patient consent for this trial.

CHICAGO (Reuters) - Shares of Northfield Laboratories Inc. <NFLD.O> plunged by as much as 27 percent on Wednesday after a Wall Street Journal article called into question the safety of its experimental blood substitute.

The front page Journal article described a clinical trial of the blood substitute PolyHeme, in which about 12 percent of patients on the product suffered heart attacks and two out of 81 patients died. The trial results were not published and no patients in the control group receiving real blood suffered a heart attack, according to the story.

PolyHeme is being tested to treat trauma patients, in some cases without patients' consent, according to the article.

http://today.reuters.com/sponsoredb..._N22328049_RTRUKOC_0_US-NORTHFIELD-STOCKS.xml

http://www.businessweek.com/ap/financialnews/D8FUC5J08.htm?campaign_id=apn_home_down&chan=db

The government website.
http://www.clinicaltrials.gov/ct/sh...onid=57195D7A71E877B771F2648934B637C6?order=1
 
Top